ASX:CSL 9 June 2026 - 29 June 2026

CSL Limited inched up Monday, putting a price tag on its new European drug setback. The gain left CSL shares at A$115.39, up 0.45%. The S&P/ASX 200 did better, ending 0.68% higher at 8,823.40. CSL picked up 22.49% in the last four weeks, but shares are still off 51.82% in the past year. The rally was no broad sign of support. Data is from June 29, Trading Economics.

CSL Ltd slipped 0.7% to end at A$112.04 Tuesday. Shares hit A$115.80 during the session but closed just 35 cents above their low for the day. The S&P/ASX 200 dropped 0.3% to 8,787. CSL’s two-day slide wiped out A$4.28, a bit more than half of Friday’s A$8.24 jump. No new ASX filings have shown up on CSL’s investor site since June 9. That points to the fall coming from some caution on the early-stage turnaround, not fresh news from the company.

CSL Limited gave up 2.96% to finish at A$112.88 on Monday, pulling back after Friday’s 7.62% surge. The rally faded as buyers did not push the stock higher, with no new corporate catalysts. The Australian cash market was closed at press time. Trading is set to resume as usual on Tuesday. The scale of the move stands out. CSL saw 8.16 million shares trade on Friday, about 3.7x its usual daily volume. The stock started Monday at A$116.25, down seven cents from the Friday close, then dropped to A$110.89. This kind of trade lines up more with a wave of buyers hitting ready sellers than a new earnings event.

CSL Limited is set for Monday after jumping 7.6% on Friday to end at A$116.32, its biggest one-day gain since February 2022. Healthcare outperformed as the S&P/ASX 200 lost 0.93%. Cochlear ended up 3.4%, while Pro Medicus finished 3.1% higher. The market did not trade on Sunday. CSL’s rebound stands out after a steep de-rating among big Australian stocks. The stock closed Friday more than 29% above its June 3 low of A$90. Still, CSL shares have dropped 37.7% in 2026 and are down 55.1% for the financial year. Even with the sharp move up, the price is coming off distressed levels, not signaling any clear shift in the company’s earnings direction.

CSL Ltd rallied hard Friday, gaining 7.6% to A$116.32 and closing at its high for the day, even as the S&P/ASX 200 slid 0.92% to 8,828.7. The stock, long out of favor with sellers, moved higher while most of the market fell. With the exchange shut for the weekend, the question is set for Monday. Did this rally in CSL stick, or was it just a quick bounce as positions shifted? CSL gave no new operating details with the move. Its investor page lists the latest ASX release from June 9. The simple read is the price moved before the business story did.

CSL Limited ended Thursday at A$108.08, up A$1.29. Shares traded between A$105.90 and A$108.44 during the session. The broader Australian index dropped 55.2 points to 8,911.1. S&P/ASX 200 ended its four-day winning streak. Still, healthcare names gained 0.35%, with buyers stepping in for weaker medical stocks. CSL led the group, climbing faster than the broader sector.

CSL Ltd finished a bit stronger in the last ASX session, ending at A$106.79 on Wednesday with the Australian cash market already outside its standard hours at the dateline. ASX normal trading goes from around 09:59:45 to 16:00 Sydney time. CSL isn't trading as a typical defensive healthcare stock anymore. It’s being seen as a turnaround play. The stock is up 7.36% from last week’s close. Shares are still down 38.76% for the year and 55.82% for FY2026.

CSL Limited was last at A$106.25, up A$0.72 or 0.68% late Tuesday, trading between A$104.74 and A$106.70. Shares have bounced 15.19% from the June 3 low, but the stock is still 60.94% below its 52-week high at A$272.00. Traders described the session as tentative rebound buying, not a real change in sentiment. ASX stocks hardly moved, with a few names ticking up. The S&P/ASX 200 ended higher by just 3.7 points at 8,917.70 after the Reserve Bank of Australia left rates steady at 4.35%. CSL could benefit if the index keeps firm and money shifts to large caps. Still, there are questions hanging over earnings, assets, and management's decisions.

Melbourne, June 16, 2026, 05:04. CSL Limited shares dropped again Tuesday after falling on Monday. Shares ended at A$105.53, down from A$107.51 at Friday’s close, Investing.com data shows. That comes after a short run higher—Intelligent Investor reported CSL was up 9.8% in the week to Friday. Despite the bounce, CSL is lagging in 2026 and this financial year.

Sydney, June 14, 2026, 23:20. CSL Limited’s share price is back in focus after the ASX healthcare heavyweight staged a relief rally, closing Friday at A$107.51, up 0.26%, with daily volume of about 1.95 million shares. The move capped a stronger week for a stock that had traded as low as A$90.00 earlier in June and remains far below its 52-week high of A$275.79, leaving investors to decide whether the bounce marks the start of a repair phase or just a rebound from oversold levels.

CSL Limited shares ended Friday at A$107.51, up 28 cents, or 0.26%. That’s off delayed market data. The stock's move was modest and trailed the 1.98% jump for the Australian market. CSL’s market cap hovered near A$52.18 billion. The stock has drawn extra focus as one of the ASX’s key turnaround names following its sharp de-rating this year. CSL surged 4.16% to A$107.23 on Thursday, hitting an intraday high of A$108.46. The Bull called CSL one of the ASX 200’s late-session standouts. The move came after a run of selling that had weighed on the stock. While shares often climb when the outlook for earnings improves, risk premiums fall, or bargain hunters return, this bounce looked like more of a

CSL Limited jumped 4.16% to close at A$107.23 on Thursday, snapping back after a rough patch for the healthcare favorite. Shares moved between A$102.15 and A$108.46. About 2.8 million CSL shares traded, topping the usual volume for the name. The move helped lift the ASX healthcare sector, as CSL saw clear buying interest. ASX slips as oil climbs on Mideast worries Australian shares edged lower, with the S&P/ASX 200 down 20.10 points or 0.23% to 8,633.20. The All Ordinaries lost 0.23% to finish at 8,836.70. Tension in the Middle East boosted oil, hitting sentiment. Healthcare and energy were firmer. CSL and Pro Medicus were among healthcare gainers. Banks and tech stocks pulled the index lower.

CSL Limited traded back above the A$100 mark on Wednesday as the stock picked up after last month’s profit warning. Buyers moved into healthcare names and checked if CSL’s reset had been digested by the market. CSL closed at A$102.95, gaining 3.5% from Tuesday’s A$99.47 finish. CSL’s jump wasn’t just a routine bounce. Market Index puts the stock up more than 14% from its June 3 low, and Intelligent Investor numbers have it gaining 11.23% over the last seven days. Still, CSL shares are off 42.67% in 2026, pointing to the drop in investor confidence.

CSL Ltd shares rose on Tuesday, standing out in a softer Australian market, as healthcare buying helped the biotech close 1.59% higher at A$99.47. ResMed gained 1.30% and Ramsay Health Care added 2.79%, putting CSL’s move in a wider defensive-healthcare bid rather than an isolated stock bounce. The broader market did not follow. The S&P/ASX 200 lost 0.24% at the Sydney close, with losses in gold, metals and mining, and materials dragging the index lower; falling stocks outnumbered risers by almost two to one.